TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03790553

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Different total radiotherapy dose between two arms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Different total radiotherapy dose between two arms.
Study: NCT02894970

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.

Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.
Study: NCT00264303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: 5mg oral capsules, once daily, 4 week duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: 5mg oral capsules, once daily, 4 week duration
Study: NCT03821103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic enhanced arm
Description: Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
Study: NCT03355339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binasal occlusion
Description: Binasal occlusion glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No binasal occlusion
Description: Non-occluded glasses
Study: NCT00949000

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD Implantation
Description: Implantation of a commercially available AnalyST or AnalyST Accel ICD
Study: NCT02799459

Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: the patient will receive a general anaesthesia do proceed at her conization

Intervention type: PROCEDURE
Intervention: Hypnosis in conization
Description: this is the experimental treatment which is allocated to the experimental group
Study: NCT04953598

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Patient undergoes diagnostic ultrasound examination
Study: NCT03255356

Intervention type: OTHER
Intervention: Survey
Description: An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
Study: NCT00919633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: subcutaneous continuous infusion at one of three doses for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: subcutaneous continuous infusion at one of three doses for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: subcutaneous continuous infusion at one of three doses for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: 1.5 μg/kg subcutaneous weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drug infusion pump
Description: pump delivery system for continuous subcutaneous infusion of interferon alfa-2b

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drug infusion pump
Description: pump delivery system for continuous subcutaneous infusion of interferon alfa-2b

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drug infusion pump
Description: pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
Study: NCT01409551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS hyperthermic chemoperfusion
Description: VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside talc slurry pleurodesis
Description: Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
Study: NCT00732862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: Hyperinsulinemic Hypoglycemic clamp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hyperinsulinemic Hypoglycemic clamp
Study: NCT01507987

Intervention type: DEVICE
Intervention: Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads
Description: Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies
Study: NCT01520805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
Study: NCT00667225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cantharidin's vehicle
Description: Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
Study: NCT02789969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone 15mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 1.5mcg/kg IV
Study: NCT00667225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin 0.7%
Description: Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
Study: NCT02248818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8108
Description: Drug: AZD8108 Single or Multiple doses administered orally as a solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
Study: NCT02912546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
Study: NCT04061369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat meal
Description: Meal consisting of conventional foods that is low (20% of energy) in fat calories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate fat meal
Description: Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: Meal consisting of conventional foods that is high (60% of energy) in fat calories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal
Description: Liquid meal that is high (60% of energy) in fat calories.
Study: NCT02075281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Glucagon-like peptide-1 analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Glucagon-like peptide-1 analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Glucagon-like peptide-1 analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: Glucagon-like peptide-1 analogue

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04407689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Study: NCT04609488

Intervention type: DIAGNOSTIC_TEST
Intervention: Surfactant assessment
Description: To determine surfactant levels in lung fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: Surfactant assessment
Description: To determine surfactant levels in lung fluid
Study: NCT01877148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
Study: NCT00508053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small stitches

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mass closure
Study: NCT05234840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: 1. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg triamcinolone with 1% lidocaine, total of 2 ml
Study: NCT04497389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Fluid
Description: Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
Study: NCT01796626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX module
Description: The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX module
Description: The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
Study: NCT00876564

Intervention type: OTHER
Group type: OTHER
Intervention: Trauma patients
Study: NCT03843853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg d1
Study: NCT04293003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting
Description: 6-hour fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate
Description: Consumption of a zero-carbohydrate breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean
Description: Consumption of a Mediterranean-type breakfast
Study: NCT03297177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Closed System, Digestive Isolation \& Concentration of AD-cSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline Infusion
Description: Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
Study: NCT02136134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (Bortezomib)
Description: VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VELCADE (Bortezomib)
Description: VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Study: NCT01450384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT02750449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sun screening Sport Lotion, (BAY987516)
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: This site is patched without treatment as control
Study: NCT02591953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guidance
Description: Using ultrasound-guidance to perform a corticosteroid injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guidance
Description: Using landmark-guidance to perform a corticosteroid injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Corticosteroid used in injection (40 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Corticosteroid used in injection (40 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%
Description: Anesthesic used in injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Description: Anesthesic used in injection
Study: NCT01588964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
Study: NCT04542967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out.
Study: NCT04677218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction with retensioned hamstring autograft
Description: After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft
Description: After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
Study: NCT01355276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinitapride
Description: cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg for each dose ,30 mg/daily, for 4 weeks
Study: NCT02548975

Intervention type: DRUG
Intervention: Statin, beta blocker
Description: Patients receiving either statin or beta blockers prior to cardiac surgery.
Study: NCT03076112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes